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Prolonged low-grade inflammation or smoldering inflammation is a hallmark of cancer. 
Mast cells form a heterogeneous population of immune cells with differences in their 
ultra-structure, morphology, mediator content, and surface receptors. Mast cells are 
widely distributed throughout all tissues and are stromal components of the inflammatory 
microenvironment that modulates tumor initiation and development. Although canoni-
cally associated with allergic disorders, mast cells are a major source of pro-tumorigenic 
(e.g., angiogenic and lymphangiogenic factors) and antitumorigenic molecules (e.g., 
TNF-α and IL-9), depending on the milieu. In certain neoplasias (e.g., gastric, thyroid 
and Hodgkin’s lymphoma) mast cells play a pro-tumorigenic role, in others (e.g., breast 
cancer) a protective role, whereas in yet others they are apparently innocent bystanders. 
These seemingly conflicting results suggest that the role of mast cells and their mediators 
could be cancer specific. The microlocalization (e.g., peritumoral vs intratumoral) of mast 
cells is another important aspect in the initiation/progression of solid and hematologic 
tumors. Increasing evidence in certain experimental models indicates that targeting mast 
cells and/or their mediators represent a potential therapeutic target in cancer. Thus, 
mast cells deserve focused consideration also as therapeutic targets in different types 
of tumors. There are many unanswered questions that should be addressed before we 
understand whether mast cells are an ally, adversary, or innocent bystanders in human 
cancers.
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iNTRODUCTiON
Mast cells were first identified in human tumors and named by Paul Ehrlich (1, 2). These cells are 
present in all classes of vertebrates, and it has been estimated that they have emerged >500 mil-
lion years ago, long before the development of adaptive immunity (3). Mast cells are distributed 
throughout nearly all human tissues and often in close proximity to epithelia, fibroblasts, blood and 
lymphatic vessels, and nerves (4).
Human mast cells form a heterogeneous population of cells with differences in their ultrastruc-
ture, morphology, mediator content, and surface receptors (4, 5). Human mast cells derive from 
CD34+, CD117+ pluripotent hematopoietic stem cells, which arise in the bone marrow (6). Mast cell 
progenitors enter the circulation and subsequently complete their maturation in tissues. These cells 
store and release upon activation a wide spectrum of biologically active mediators that individually 
have been shown to have potential positive or negative effects on various target cells (7). Increasing 
evidence indicates that mast cells act as sentinels of the surrounding environment, with the 
FigURe 1 | Some of the surface receptors expressed by human mast cells. Human mast cells express the tetrameric high-affinity receptor for IgE (FcεRI) and 
the FcγRIIA, and their cross-linking induces the release of pro-inflammatory and immunomodulatory mediators. Mast cell expresses the KIT receptor (CD117), which 
is activated by stem cell factor. These cells express a plethora of receptors, such as toll-like receptor (TLR) 2, TLR4, TLR5, TLR6, receptors for chemokines (CCR2, 
CCR3, CXCR1, CXCR2, CXCR3, and CXCR4), two receptors for cysteinyl leukotriene (CysLTR1 and CysLTR2), two leukotriene B4 receptors (BLT1 and BLT2), the 
prostaglandin D2 receptor (CRTH2), the prostaglandin E2 receptor (EP2), the cannabinoid CB1 receptor, two adenosine receptors (A2B and A3), and histamine H4 
receptor (H4R). Mast cells express receptor for various cytokines (IL-4Rα, IL-5Rα, IFN-γRα, ST2). The MAS-related G protein coupled receptor (MRGPRX2) can be 
activated by neuromuscular blocking drugs, neuropeptides (SP and VIP), and eosinophil cationic proteins (MBP and EPX). These cells also express receptors for 
vascular endothelial growth factors (VEGFR1 and VEGFR2), and VEGFR co-receptors, neuropilin-1 and neuropilin-2 (NRP1 and NRP2), for anaphylatoxins (C5aR1/
CD88, C5aR2, and C3aR), and the high-affinity urokinase plasminogen activator receptor (uPAR). Human mast cells also express co-receptors for T-cell activation 
[CD40 ligand (CD40L), tumor necrosis factor superfamily member 4 (OX40L), inducible costimulator ligand (ICOS-L), programmed death ligands (PD-L1 and PD-L2)] 
[Slightly modified with permission of Springer Nature from Borriello et al. (15)].
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capacity to rapidly perceive tissue insults and initiate biochemical 
programs of inflammation or repair.
Mast cells are activated not only by IgE (8), specific antigens (5), 
and superallergens (9, 10), the main mechanisms which account 
for their function in allergic disorders, but also by a plethora of 
immunologic and non-immunologic stimuli (11–14). Figure  1 
schematically illustrates the constellation of surface receptors 
expressed by human mast cells.
Mast cells and their mediators have been canonically associ-
ated with a detrimental role in allergic diseases (4, 5), but these 
cells can induce a protective immune response of the host against 
noxious substances (16, 17), viral (18) and microbial pathogens 
(19). Interestingly, epidemiological (20, 21) and experimental 
studies (22) indicate an inverse association between IgE-mediated 
allergies and cancer, implying tumor-protective effect of IgE.
The initiation and progression of cancer are multistep pro-
cesses characterized by the accumulation of a variable number 
of genetic and epigenetic alterations (23). The immunosurveil-
lance system recognizes and eliminates mutant cells constantly 
generated (24). However, immune-resistant cancer cells can slip 
through this system and proceed to develop tumors (25).
Normal microenvironment [immune cells, fibroblasts, blood 
and lymphatic vessels, and interstitial extracellular matrix (ECM)] 
plays a central role in maintaining tissue homeostasis and is a 
barrier to tumorigenesis (26). Incorrect signals (chemokines, 
cytokines, reactive oxygen species, lipid mediators, etc.) from an 
aberrant microenvironment alter tissue homeostasis and initiate/
promote tumor growth. Thus, the multiple interactions between 
stromal and tumor cells are crucial for the initial phases of tumor 
development.
Prolonged low-grade inflammation or smoldering inflamma-
tion is a hallmark of cancer (27, 28). Several cells of the innate and 
adaptive immune system (macrophages, mast cells, lymphocytes, 
neutrophils, NK, and NK T cells) are stromal components of the 
inflammatory microenvironment that can promote the develop-
ment of experimental and human tumors (29, 30).
wHY ARe MAST CeLLS iNCReASeD  
iN TUMORS?
The presence of mast cells in human tumors, initially reported 
by Ehrlich (1, 2), was extended by Eugen Westphal (31). Tumor-
associated mast cells (TAMCs) are present in the microenviron-
ment of several human solid (32–46) and hematologic tumors 
(47–55).
Peritumoral and/or intratumoral mast cell density is increased 
in different types of human cancer (56). Tumor cells produce 
several chemotactic factors acting on receptors expressed by 
mast cells. Stem cell factor (SCF) (13, 57), also produced by 
TAbLe 1 | Pro-tumorigenic role of mast cells in human tumors.
Type of cancer Mast cell staining Reference
Angioimmunoblastic T-cell 
lymphoma
Tryptase (50)
Bladder Tryptase (67)
Colorectal Giemsa (68)
Toluidine blue/tryptase (69)
Tryptase (70–73)
Cutaneous lymphoma Tryptase (48)
Esophagus Toluidine blue (74)
Follicular lymphoma Tryptase (51)
Gastric Toluidine blue (75)
Chymase (76)
Tryptase (77, 78)
Hepatocellular Tryptase (79)
Hodgkin’s lymphoma Tryptase (53–55)
Lung Tryptase (80, 81)
CD117 (82)
Malignant pleural effusion May-Gruenwald–Giemsa 
toluidine blue
(35)
Melanoma Gene expression/toluidine blue (83)
Tryptase (41, 45)
Merkel cell carcinoma Tryptase (33)
Pancreas Tryptase (37, 84–86)
Plasmacytoma Toluidine blue (47)
Tryptase (49)
Prostate Tryptase (36, 40, 87, 88)
Splenic marginal zone 
lymphoma
Tryptase (52)
Thyroid Tryptase (38, 61)
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mast cells (58), activates the mast cell Kit receptor (CD117), 
vascular endothelial growth factors (VEGFs) act on VEGFR-1 
and VEGFR-2 (38, 59), angiopoietin 1 (Ang1) acts on Tie2 
receptor (60), and CXCL8/IL-8 acts on CXCR1 and CXCR2 
(61). Mast cells express CCR2, CXCR2, and CXCR3, which can 
be important for TAMC localization because their respective 
ligands, CCL2, CXCL1, and CXCL10, are produced by human 
tumors (35, 38). PGE2 and histamine are chemotactic for mature 
mast cells through the engagement of EP2 receptor (62, 63) and 
H4R, respectively (64). LTB4 may be involved in recruitment of 
mast cell progenitors from the circulation via the activation of 
BLT1 and BLT2 (65). Finally osteopontin (OP), which is upregu-
lated in human cancer (35), induces mast cell migration (66) and 
degranulation (35).
THe CONTRibUTiON OF MAST CeLLS  
TO CANCeR iS TUMOR DePeNDeNT
The increasing heterogeneity of different subsets of immune cells 
(e.g., macrophages, T helper cells, mast cells, neutrophils, NK, NK 
T cells, etc.), their plasticity, and their reciprocal interactions have 
complicated the comprehension of the role of the inflammatory 
microenvironment in tumor initiation and development (29).
A large number of studies have tried to identify the contribu-
tory functions of TAMCs in tumor growth. In the majority of 
studies, TAMCs appear functional—either actively promoting 
or suppressing tumor development and growth—whereas in a 
few cases they may be simple inert bystanders. In several stud-
ies, mast cells appear to play a pro-tumorigenic role in human 
(Table  1) and experimental tumors (Table  2). Evidence for an 
antitumorigenic role for mast cells is provided in Table 3. Studies 
supporting a non-contributing role of mast cells in tumors are 
outlined in Table 4.
In several solid tumors, such as thyroid (38, 61), gastric 
(75–77, 122), pancreas (37, 84, 85, 94, 95, 123), bladder cancers 
(67), and Merkel cell carcinoma (33), mast cells always appear 
to be pro-tumorigenic. Similarly, in several hematologic tumors, 
such as different types of Hodgkin’s (53–55) and non-Hodgkin’s 
lymphoma (48, 50, 52), and plasmacytoma (47, 96), mast cells are 
associated with poor prognosis. There are certain tumors such as 
breast cancer (106, 107, 109) in which mast cells always appear 
to play an antitumorigenic role. The role of mast cells in the 
pathogenesis of human melanomas is still unclear and appears to 
depend on both the microlocalization of these cells (43) and the 
subtypes of tumor (83).
These apparently conflicting results are intriguing and suggest 
that the role of mast cells and their mediators in tumors could be 
cancer specific. Figure 2 schematically illustrates the role of mast 
cells in different human tumors.
ROLe OF TAMCs iN TUMOR 
ANgiOgeNeSiS AND 
LYMPHANgiOgeNeSiS
Angiogenesis, the formation of new blood vessels, is an essential 
process for supplying growing malignant tissues with essential 
nutrients and oxygen (124). Lymphangiogenesis, the formation 
of new lymphatic vessels, is important in the development of 
metastases (124). Judah Folkman, the father of angiogenesis, 
suggested that mast cells and macrophages could be attracted 
by chemotactic molecules produced by tumor cells and could 
be an important source of proangiogenic factors (125). Several 
groups have demonstrated that mast cells produce several 
proangiogenic (VEGF-A, VEGF-B, and FGF-2) (126–130) and 
lymphangiogenic factors (VEGF-C and -D) (38, 59, 131). In 
addition, we have found that VEGFs are chemotactic for mast 
cells (59), indicating that mast cells are a target, in addition to 
be a source, for VEGFs (132). Several studies have highlighted 
the association and/or the correlation in human tumors between 
increased mast cell density and angiogenesis by evaluating the 
expression of the proangiogenic isoform VEGF-A (42, 45, 70, 
80, 96, 123).
The VEGF-A gene can be alternatively spliced to form the 
proangiogenic VEGF-A165 and the antiangiogenic VEGF-A165b 
(133). The vast majority of the studies performed so far evalu-
ated only the proangiogenic isoforms, whereas in certain tumors 
the antiangiogenic VEGF-A165b isoform is dominant (134). This 
finding suggests that the majority of results on VEGF-A plasma 
TAbLe 4 | Non-contributing role of mast cells in tumors.
Type of cancer Mast cell staining Reference
experimental tumors
Colorectal Wright–Giemsa (117)
Skin Toluidine blue/chloroacetate 
esterase
(118)
Human tumors
Colorectal Tryptase (119)
Non-small cell lung cancer Giemsa (120)
Renal Toluidine blue (121)
TAbLe 3 | Antitumorigenic role of mast cells in tumors.
Type of cancer Mast cell staining Reference
experimental tumors
Intestine Chloroacetate esterase/
chymase
(101)
Tryptase/CD117 (102)
Melanoma NE (103)
Prostate Toluidine blue (40)
Skin Tryptase/CD117 (102)
Giemsa (104)
Human tumors
Diffuse large B-cell lymphoma Tryptase (105)
Breast cancer CD117 (106)
Tryptase (107)
Alcian blue/Giemsa (108)
CD117 (109)
Colorectal Tryptase/chymase (110)
Lung Tryptase/chymase (111)
Mesothelioma Tryptase/chymase (112)
Melanoma Tryptase/chymase (43)
Non-small-cell lung cancer Tryptase (113)
Tryptase/chymase (114)
Ovarian cancer Tryptase (115)
Pancreas CD117 (71)
Prostate CD117 (116)
NE, not examined.
TAbLe 2 | Pro-tumorigenic role of mast cells in experimental tumors.
Type of cancer Mast cell staining Reference
Bladder cancer Toluidine blue (89)
Tryptase (67)
Cholangiocarcinoma Toluidine blue (46)
Colon Toluidine blue/proteases (90)
Alcian blue/toluidine blue (91)
Chloroacetate esterase (71)
Cutaneous lymphoma Toluidine blue (48)
Hepatocellular NE (13)
Malignant pleural effusion May-Gruenwald–Giemsa/toluidine blue (35)
Melanoma NE (92)
Alcian blue–safranin (14)
NE (93)
Gene expression/toluidine blue (83)
Pancreas Toluidine blue (94)
Tryptase (84, 85)
CD117 (95)
Tryptase (37)
Plasmacytoma Toluidine blue (96)
Prostate Tryptase/toluidine blue (40)
Toluidine blue (87, 97)
Skin Chloroacetate esterase/hematoxylin (98)
Chloroacetate esterase (11)
Chloroacetate esterase/toluidine blue (99)
Thyroid Tryptase (38, 61)
Waldenstrom’s 
macroglobulinemia
CD117/FcεRI/tryptase (100)
NE, not examined.
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levels in cancer need to be reinterpreted or require repeating with 
tools that can differentiate between the two isoforms of VEGF-A 
(135). For instance, we have recently demonstrated that human 
neutrophils, under certain circumstances, can produce both 
pro- and antiangiogenic isoforms of VEGF-A (136). The role of 
different pro- and antiangiogenic isoforms of VEGFs produced 
by TAMCs in primary cancers and in the formation of metastases 
needs further investigation.
Human mast cells produce different matrix metalloproteinases 
(e.g., MMP-9) (137) and proteases (tryptase and chymase), which 
regulate the digestion of ECM favoring the implantation of cancer 
cells in an aberrant microenvironment (13, 98).
Vascular endothelial growth factor-C, released by melanoma 
cells (138), TAMs (139), and TAMCs (59), likely represents a 
major lymphangiogenic factor in this tumor. Mast cells can be 
found in metastatic lymph nodes of cancer patients (140), and 
the role of lymphangiogenic factors in the formation of metastasis 
should be further addressed.
Epithelial-to-mesenchymal transition (EMT) is a mechanism 
by which tumor cells gain metastatic features and contribute to 
chemotherapy drug resistance (141, 142). In addition, in the con-
text of tumors, EMT can generate cells with stem-like properties 
(e.g., stemness) (143). We have demonstrated that mast cells can 
induce EMT and stem cell features in human cancer through the 
production of CXCL8/IL-8 (61).
THe ROLe OF MAST CeLLS vARieS 
ACCORDiNg TO THe STAge  
OF TUMORS
A recent study found that low mast cell count in perilesional 
stroma of deeply invasive melanomas predicted poor survival 
(43). By contrast, mast cell density was not correlated with 
prognosis in superficially invasive melanomas. The latter findings 
suggest that the role of mast cells in melanoma is dependent also 
on the stage of the tumor. The role(s) of these cells in human and 
experimental melanoma requires additional studies.
FigURe 2 | Roles of mast cells in human tumors. In red boxes are indicated the tumors in which mast cells play a pro-tumorigenic role. In green boxes are 
those tumors in which mast cells appear to play a protective role. In mixed red/green boxes are presented tumors in which mast cells play both a pro- and 
antitumorigenic role in different studies.
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Pittoni et  al. found that in prostate cancer mast cells exert 
different functions according to tumor stage. Mast cells were 
pro-tumorigenic in the initial stages of prostate cancer by sup-
plying MMP-9 in the microenvironment, but became dispensable 
at later stages (40, 144).
In stage I non-small-cell lung cancer (NSCLC), but not in stage 
II, peritumoral but not intratumoral mast cell (tryptase+ chymase+) 
density was an independent favorable prognostic factor (111).
Vascular endothelial growth factor-B, an angiogenic factor pro-
duced by human macrophages and mast cells (59, 139), could play 
a role in early colon cancer development at the stage of adenoma 
formation (145).
THe ROLe OF MAST CeLLS iN TUMORS 
vARieS ACCORDiNg TO THeiR 
MiCROLOCALiZATiON
The vast majority of initial studies evaluating mast cell density 
in different cancers did not examine differences between the 
periphery and the center of tumors. There is increasing evidence 
that different stages of tumors can be associated with qualita-
tive and quantitative changes in different types of immune cells 
in the periphery and center of tumors (146, 147). The pro- or 
antitumorigenic role of mast cells in different types of melanomas 
remains controversial (83, 148). Siiskonen and collaborators 
found that tryptase+ chymase+ mast cells in perilesional stroma 
of melanoma play a protective role (43). In NSCLC, mast cell 
infiltration of tumor islets confers a survival advantage indepen-
dently of tumor stage (113, 114). In another study, it was found 
that only in stage I NSCLC increased peritumoral mast cells were 
associated with a better prognosis (111). In pancreatic ductal 
adenocarcinoma, mast cell density in the intratumoral border 
zone, but not the peritumoral or the intratumoral center zone, 
was associated with a worse prognosis (86). In prostate cancer, 
high intratumoral mast cell density was initially associated with 
good prognosis (116). Subsequently, it was reported that intratu-
moral mast cells inhibited tumor growth, whereas peritumoral 
mast cells stimulated human prostate cancer (36).
Mast cells are increased in patients with both cutaneous 
T-cell lymphoma and cutaneous B-cell lymphoma compared 
with normal skin, particularly at the periphery of the tumors. 
Interestingly, the density of mast cells in the center of tumors 
was similar to normal skin. The density of peripheral mast cells 
correlated with disease progression (48).
Collectively, these findings suggest that the microlocalization 
of mast cells is an important aspect in the initiation and progres-
sion of several tumors.
FigURe 3 | Possible mechanisms by which mast cells and their mediators may play a pro-tumorigenic or an antitumorigenic role. Mast cells in tumor 
microenvironment can promote tumor initiation and progression through the release of ROS, angiogenic and lymphangiogenic factors, and proteases, the induction 
of epithelial-to-mesenchymal transition and stemness. Mast cells can also activate STAT-3, contribute to immunosuppression and macrophage M2 polarization, and 
stimulate proliferation of tumor cells. Mast cells can exhibit antitumor activity through direct tumor cell cytotoxicity mediated by ROS and TNF-α or indirectly through 
the release of heparin, IL-9, and stimulation of dendritic cell maturation.
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Figure 3 schematically illustrates the mechanisms by which 
mast cells and some of their mediators may play a pro-tumorigenic 
or an antitumorigenic role.
wHiCH ARe THe ACTivATORS OF TAMCs 
iN TUMOR MiCROeNviRONMeNTS?
Peritumoral and intratumoral mast cells operate in an inflam-
matory microenvironment characterized by hypoxia, the accu-
mulation of lactic acid, adenosine, PGE2, IFN-γ, and by low pH 
(149–151). This milieu is likely to influence mast cell recruitment 
and activation. Mast cells can be recruited by SCF produced by 
several tumors and by mast cells themselves (13, 58). Mast cells 
can be recruited by VEGFs and Ang1 produced by tumor and 
immune cells through the engagement of VEGFR-1/VEGFR-2 
and Tie2, respectively, expressed by human mast cells (38, 59, 60).
Hypoxia, a feature of tumor microenvironment (150), acti-
vates human mast cells to release IL-6 (152) and VEGF-A (153). 
Adenosine, produced by tumor cells and mast cells (154), is 
markedly increased (150) and is an immunosuppressive factor in 
tumor microenvironment (13). Adenosine potentiates histamine 
release (155) and the production of angiogenic factors from human 
mast cells and macrophages (61, 139, 156). Cyclooxygenase 2, 
overexpressed in tumors (150), generates PGE2 which induces 
angiogenic and lymphangiogenic factors from human mast cells 
(59). Several chemokines (CXCL1, CXCL10, and CXCL12) can 
activate mast cells and enhance mast cell secretion of CXCL8/IL-8 
(38, 157). Thus, these chemokines can promote angiogenesis/
lymphangiogenesis via the recruitment of mast cells to the edge 
of solid tumors.
The impact of IgE-mediated activation of mast cells on tumor 
development and progression has been investigated (158). 
Monomeric IgE, in the absence of antigen, induced VEGF-A 
production from mast cells and increased melanoma growth (8). 
Increased expression of immunoglobulin free light chains (FLC) 
was found within stroma of various human cancers. In a murine 
B16F10 melanoma model, inhibition of FLC-mediated mast cell 
activation reduced tumor growth (12). Alarmins are upregulated 
in cancers (159) and can activate mast cells (160). IL-33 is upregu-
lated in squamous cell carcinoma (SCC) (161), and mast cell acti-
vation by IL-33 occurs in skin cancers (161). IL-33 induces the 
production of GM-CSF, CXCL8/IL-8, and VEGF-A from mast 
cells (128, 162, 163). In addition to the high-affinity receptor for 
IgE (FcεRI), human mast cells express the IgG receptors FcγRIIA 
and FcγRI (164, 165). FcγRI is upregulated by IFN-γ which is 
7Varricchi et al. Mast Cells in Cancer
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highly expressed in tumors. In the tumor microenvironment, 
antitumor IgG immune complexes may activate mast cells (166). 
OP, upregulated in human cancer (167), is produced by mast 
cells (66) and induces their migration and degranulation (35, 66). 
Platelet-activating factor, produced by human mast cells (168), 
upregulates CXCR4 on mast cells and promotes their migration 
to lymph nodes (169, 170).
In summary, a plethora of immunologic and non-immunologic 
factors present in tumor microenvironment can activate TAMCs.
MAST CeLLS AS A POTeNTiAL 
THeRAPeUTiC TARgeT iN CANCeR
Several therapeutic strategies have been envisioned to limit tumor 
growth by targeting mast cells and their mediators. Mast cells 
play a pro-tumorigenic role in human bladder cancer through 
stimulating estrogen receptor β (ERβ) (67). In a murine model 
of bladder cancer, these authors showed that a selective ERβ 
antagonist inhibited mast cell-promoted tumor growth. It has 
been found that mast cells can promote the proliferation of colon 
cancer in vivo (71). Injection of Fcε-PE40 chimeric toxin, which 
induced mast cell apoptosis, inhibited colon tumor development 
in vivo.
Pharmacologic inhibition of mast cell degranulation by 
cromolyn inhibited Myc-induced pancreatic islet tumors (94), 
experimental pancreatic and thyroid cancer (37, 38, 95), and 
cholangiocarcinoma (46).
Pittoni and collaborators have demonstrated that pharma-
cologic inhibition by cromolyn and genetic ablation of mast 
cells inhibited prostate cancer in mice (40). However, mast cells 
protect from a malignant neuroendocrine tumor. It has been 
shown that mast cells can promote prostate cancer chemotherapy 
and radiotherapy resistance via modulation of p38/p53/p21. The 
authors suggested that targeting these signaling pathways may 
help to suppress chemo- and radiotherapy resistance in prostate 
cancer (97). In a mouse model, mast cells enhanced prostate 
cancer growth via modulation of androgen receptor and increas-
ing MMP-9 expression (87). The authors suggested that targeting 
these mast cell-androgen receptor signals may inhibit tumor 
growth.
The UV wavelengths in sunlight are the prime etiological 
cause of skin cancers, including basal cell carcinoma and SCC. 
Exposure to UV affects skin mast cell migration by altering the 
CXCR4–CXCL12 axis (99). The pharmacological blockage of the 
CXCR4–CXCL12 pathway inhibited sunlight-induced skin cancer.
Collectively, these findings indicate that mast cells and their 
mediators deserve focused consideration as therapeutic targets 
in different types of cancer.
OUTSTANDiNg QUeSTiONS
There is compelling evidence that human mast cells isolated 
from various anatomical sites respond to different stimuli and 
release distinct mediators (14, 59, 160, 166, 171). Peritumoral 
and intratumoral TAMCs are embedded by a wide spectrum of 
mediators and in close contact with several stromal cells. It will 
be important to identify the stimuli that can activate TAMCs in 
different tumor microenvironments. Similarly, it will be impor-
tant to identify preformed and de novo synthesized mediators 
released in situ by TAMCs.
Studies on mast cell biology are routinely conducted at physi-
ological pH and normoxia. By contrast, the metabolic phenotype 
of tumors is characterized by low pH and areas of either hypoxia 
or normoxia (150). Tumor-associated macrophages in normoxic 
tumor tissues express M1 markers, whereas those in hypoxic 
tumor tissues preferentially express M2 markers (172). These 
findings caution against the over interpretation of results from 
studies of whole TAMC populations. It will be of fundamental 
importance to investigate how hypoxic conditions and metabo-
lism activate/modulate the production of pro-inflammatory and 
angiogenic/lymphangiogenic factors from TAMCs. Proteomic 
(173) and lipidomic analyses (174) of mast cells will help to 
characterize the proangiogenic and antitumorigenic profiles of 
TAMCs from different human tumors.
Analysis of mast cells in draining lymph nodes and in ectopic 
lymphoid structures of tumors has only recently begun (35, 43). 
The role of mast cells in draining lymph nodes, in tertiary lym-
phoid tissues, and at metastatic sites of different tumors remains 
to be explored.
IgE has been suggested to play a protective role in tumor growth 
(21, 158). Additional studies should investigate the role, if any, of 
IgE-mediated activation of mast cells in different human tumors.
The pro- or antitumorigenic role(s) of mast cells in different 
human tumors appears to be generally, but not always, cancer 
specific. We cannot exclude the possibility that subpopulation 
of TAMCs could play different, even opposite effects in various 
types/subtypes of tumors.
There is preliminary evidence that peritumoral mast cells 
(48) play different roles compared to intratumoral mast cells (36, 
113, 114). Studies in other experimental and human tumors will 
clarify whether the microlocalization of mast cells can markedly 
influence their effects.
Within the last years, gene expression profiling has demon-
strated that several individual human cancers (e.g., melanoma, gas-
tric, lung, and breast cancers) are heterogeneous with a spectrum 
of molecular changes (83, 175–178). The complex heterogeneity 
(spatial, temporal, intratumor, intertumor) of the tumor micro-
environment adds an additional layer of complexity (179, 180). 
An important task will be to correlate the role of TAMCs in dif-
ferent subtypes of human cancers as defined by genetic markers.
There is recent evidence in melanoma (43), in prostate (40), 
and in pancreatic cancer (37) that mast cells can play different 
roles in early and late phases of tumor initiation and growth. 
This fascinating hypothesis deserves to be further investigated in 
order to clarify the functional role of TAMCs in the progression 
of experimental and human cancers.
Two strains of mast cell-deficient mice with mutations 
affecting Kit, KitW/w−v (90, 91, 94, 98, 101, 104) and KitW−sh/W−sh  
(14, 35, 40, 85, 89), have been extensively used to study the role of 
mast cells in tumor growth. These mice are profoundly deficient 
in mast cells and also exhibit several other abnormalities, such 
as basophil deficiency (181, 182). Recent evidence suggests that 
basophils can play a role in human pancreatic cancer (183). New 
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Kit-independent mast cell-deficient mice (184) have been used 
to evaluate the role of mast cells in cutaneous lymphoma (48), 
malignant pleural effusion (35), and skin cancerogenesis (118). 
Collectively, results obtained with mast cell-deficient mouse 
models should be interpreted with caution because even new 
mouse mutants with unperturbed Kit function also showed some 
hematological abnormalities (184, 185).
Mast cells are plastic cells: their phenotype depends on their 
anatomical location and the physiological or pathological context 
(4, 5, 171). TAMCs are exposed in a hostile tumor environment 
to increased levels of lactate, PGE2, adenosine, IFN-γ, and a low 
pH (149, 150). This metabolic milieu can profoundly alter mast 
cell behavior. It has been shown that it is possible to reverse 
the immunosuppressive and pro-tumoral properties of tumor-
associated macrophages (186, 187). A better knowledge of the 
pro-tumorigenic profile of TAMCs could help to “re-educate” 
these cells to play an antitumorigenic role.
Tumor cells evade host immune attack by expressing several 
checkpoint inhibitors, such as programmed cell death-1 (PD-1) 
ligands (PD-L1 and PD-L2) which inhibit PD-1+ lymphocytes in 
tumor microenvironment (188). Monoclonal antibodies targeting 
the PD-1/PD-L1 pathway unleash antitumor immunity and have 
revolutionized the management of a wide spectrum of malignan-
cies (189). Certain cancer cells (e.g., melanoma) express also PD-1, 
in addition to PD-L1, providing an additional tumor intrinsic 
mechanism enhancing the pro-tumorigenic effect of PD-1/PD-L1 
axis (190). Mouse mast cells highly express PD-L1 and, to a lesser 
extent, PD-L2 (191). An important task will be to investigate the 
role of PD-L1+ TAMC in tumor microenvironment.
All the above implies that elucidation of the roles of mast cells 
in different human tumors will demand studies of increasing 
complexity beyond those assessing merely mast cell density and 
microlocalization.
CONCLUSiON
In several human and experimental tumors, mast cells and their 
mediators play a pro-tumorigenic role. However, in other tumors 
and even in the same tumor, mast cells seem to play a protective 
role. These apparently controversial results might reflect differ-
ences in stage, grade, and subtypes of tumors, different methods 
to identify mast cells (e.g., tryptase+, chymase+, toluidine blue, 
CD117+, Giemsa), or different microanatomical compartment 
(i.e., peritumoral vs intratumoral) analyzed in the various studies. 
Whatever the mechanisms, there are many unanswered questions 
that need to be addressed before we understand whether mast cells 
are an ally, adversary, or innocent bystander in human cancers.
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